Ernexa Therapeutics

(NASDAQ) ERNA

Current Price$3.60

Market Cap$111.15M

Since IPO (2021)-100%

5 Year-100%

1 Year-95%

1 Month-28%

Ernexa Therapeutics Financials at a Glance

Market Cap

$111.15M

Revenue (TTM)

$0.00

Net Income (TTM)

$14.08M

EPS (TTM)

$-3.26

P/E Ratio

-1.17

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$3.60

Volume

74,725.147

Open

$3.93

Price

$3.60

Volume

74,725.147

Open

$3.93

Previous Close

$3.81

Daily Range

$3.18 - $3.93

52-Week Range

$3.18 - $100.46

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$3.60

Volume

74,725.147

Open

$3.93

Previous Close

$3.81

Daily Range

$3.18 - $3.93

52-Week Range

$3.18 - $100.46

ERNA News

A researcher studying a sample in a petri dish

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ernexa Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Sanjeev Luther, MBA

Website

www.ernexatx.com

Headquarters

Cambridge, MA 92121, US

ERNA Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-687%

Return on Capital

-3%

Return on Assets

-2%

Earnings Yield

-85.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$111.15M

Shares Outstanding

29.15M

Volume

74.73K

Avg. Volume

71.36K

Financials (TTM)

Gross Profit

$263.00K

Operating Income

$9.32M

EBITDA

$9.06M

Operating Cash Flow

$7.02M

Capital Expenditure

$37.00K

Free Cash Flow

$7.05M

Cash & ST Invst.

$1.88M

Total Debt

$490.00K

Ernexa Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$69.00K

-7000.0%

Gross Margin

0.00%

N/A

Market Cap

$111.15M

N/A

Market Cap/Employee

$18.53M

N/A

Employees

N/A

Net Income

$1.50M

+73.9%

EBITDA

$2.02M

+7.8%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$1.39M

+33.4%

Accounts Receivable

$95.00K

-78.3%

Inventory

$0.00

N/A

Long Term Debt

$277.00K

-41.9%

Short Term Debt

$213.00K

+2.9%

Return on Assets

-2.41%

N/A

Return on Invested Capital

-3.42%

N/A

Free Cash Flow

$1.16M

+67.2%

Operating Cash Flow

$1.15M

+67.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ADAPAdaptimmune Therapeutics plc

ADAPAdaptimmune Therapeutics plc$0.05-3.00%

MPLTMapLight Therapeutics, Inc.

MPLTMapLight Therapeutics, Inc.$27.55-10.24%

OSRHOSR Holdings, Inc.

OSRHOSR Holdings, Inc.$0.58-8.92%

PMNProMIS Neurosciences, Inc.

PMNProMIS Neurosciences, Inc.$11.07+0.54%

LNAILunai Bioworks Inc.

LNAILunai Bioworks Inc.$0.36+11.41%

MBRXMoleculin Biotech, Inc.

MBRXMoleculin Biotech, Inc.$2.48-1.20%

DWTXDogwood Therapeutics, Inc.

DWTXDogwood Therapeutics, Inc.$1.39-4.79%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

CNSPCns Pharmaceuticals

CNSPCns Pharmaceuticals$8.42+2.64%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.16+0.01%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.00%

SOUNSoundHound AI

SOUNSoundHound AI$9.70+0.01%

GMEGameStop

GMEGameStop$24.58-0.07%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$45.55+0.02%

NOKNokia

NOKNokia$13.18-0.01%

Questions About ERNA

What is the current price of Ernexa Therapeutics?

Ernexa Therapeutics is trading at $3.67 per share.

What is the 52-week range for Ernexa Therapeutics?

Over the past 52 weeks, Ernexa Therapeutics has traded between $3.18 and $100.46.

How much debt does Ernexa Therapeutics have?

As of the most recent reporting period, Ernexa Therapeutics reported total debt of $490,000.

How much cash does Ernexa Therapeutics have on hand?

Ernexa Therapeutics reported $1.88M in cash and cash equivalents in its most recent financial results.

What is Ernexa Therapeutics’s dividend yield?

Ernexa Therapeutics does not currently have a dividend yield.

Ernexa Therapeutics

Ernexa Therapeutics Financials at a Glance

ERNA News

Why Brooklyn ImmunoTherapeutics Crushed the Market Today

Why Brooklyn ImmunoTherapeutics Stock Crushed It in April

Up 1,300% in the Past Month, Is This Mysterious Biotech a Buy?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Ernexa Therapeutics

ERNA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Ernexa Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ERNA

What is the current price of Ernexa Therapeutics?

What is the 52-week range for Ernexa Therapeutics?

How much debt does Ernexa Therapeutics have?

How much cash does Ernexa Therapeutics have on hand?

What is Ernexa Therapeutics’s dividend yield?

Premium Investing Services